Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018099 (
gout
)
5,192
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Rates of de novo purine synthesis in lymphoblast cell cultures derived from ten patients with
gout
were compared with those from control individuals. Since the growth rate of the culture, an assay procedure was developed to account for the variation in lymphoblast growth rates and to permit valid quantitative comparison between purine synthesis in each cell line. Clear differences were demonstrated between the rates of purine synthesis in cells from normal control subjects and those from patients with a deficiency of
hypoxanthine-guanine phosphoribosyltransferase
activity (HPRT-deficient). Lymphoblasts from the gouty patients showed purine synthesis either within the normal range or intermediate between this and the HPRT-deficient cells. In patients having normal renal function, de novo purine synthesis of lymphoblast cells correlated with the degree of urate production as reflected by the urinary excretion of urate over a 24 h period. Three patients, with demonstrable excessive production of urate in vivo, exhibited increased purine synthesis in lymphoblasts. This increased synthesis did not appear to result from any of the enzyme mutations currently recognized as responsible for abnormal purine metabolism.
...
PMID:Purine synthesis de novo in cultured lymphoblast cells derived from patients with gout. 358 99
We have previously described a 14-yr-old boy with hyperuricemia, renal failure, and accelerated purine production resistant in vivo and in vitro to purine analogs. This patient demonstrated normal red cell
hypoxanthine-guanine phosphoribosyltransferase
(
HPRT
) heat stability, electrophoresis at high pH, and activity at standard substrate levels. In the present report an abnormal
HPRT
enzyme was demonstrated by enzyme kinetic study with phosphoribosylpyrophosphate (PRPP) as the variable substrate and inhibitory studies with sodium fluoride. Apparently normal
HPRT
activity in a patient with hyperuricemia and
gout
does not exclude a functionally significant
HPRT
mutation.
...
PMID:Hypoxanthine-guanine phosphoribosyltransferase variant associated with accelerated purine synthesis. 435 74
For study of the basis of an X-linked form of
gout
in man, several clonal lines deficient in
hypoxanthine-guanine phosphoribosyltransferase
(EC 2.4.2.8) were selected from the human lymphoblast line WI-L2 by spontaneous and mutagen-induced resistance to 10 muM 8-azaguanine. Three groups could be defined: (1) clones with less than 1% of normal enzyme activity, unable to incorporate [(3)H]hypoxanthine detectable by radioautography, unable to tuilize exogenous hypoxanthine as a source of purines, and showing a 2- to 4-fold accelerated rate of production of early intermediates in de novo purine biosynthesis; (2) clones with 56-63% of normal enzyme activity, decreased incorporation per cell of [(3)H]hypoxanthine measured by radioautography, able to utilize exogenous hypoxanthine, and showing 1.2- to 2.8-fold purine overproduction; (3) clones with 10-15% of normal enzyme activity, able to utilize hypoxanthine but not incorporating amounts detectable by radioautography, and showing a 2.3- to 2.5-fold increase in purine biosynthesis. Resistant clones generated by ICR 191 mutagenesis resembled Group 1 clones. Heat inactivation studies in crude extracts from certain clones in Group 2 suggest a structural gene mutation, but no qualitative alteration in enzyme could be detected by starch gel electrophoresis. These phenotypes have persisted over at least 300 generations of nonselective growth, with retention of a diploid karyotype.
...
PMID:Expression of purine overproduction in a series of 8-azaguanine-resistant diploid human lymphoblast lines. 452
Activity of hypoxanthine-guanine and adenine phosphoribosyl transferase enzymes has been assayed in erythrocytes from 10 normal adults, 37 subjects with
gout
, and 21 mentally retarded children with high and normal urinary uric acid:creatinine ratios. These were compared with one case of known
HGPRTase
deficiency. Apart from the last subject, no cases of
HGPRTase
deficiency were found.
...
PMID:Phosphoribosyl transferase activity in normal subjects, gout patients, and children with mental retardation. 555 90
A family is described in which four affected males, spanning two generations, have hyperuricemia and
gout
accompanied by hematuria but are without severe neurologic involvement. The affected males were found to have markedly reduced levels of erythrocytic
hypoxanthine-guanine phosphoribosyltransferase
(
HGPRT
) activity; these were 5-12% with hypoxanthine and 0.5-3% with guanine as compared to controls. Erythrocytic adenine phosphoribosyltransferase (APRT) was approximately three-fold elevated in the affected individuals. The residual
HGPRT
activity in affected males enabled characterization of some of the properties of this mutation. The apparent Michaelis constants (km) for both hypoxanthine and guanine were essentially unchanged, whereas the km for PP-ribose-P was approximately 10-20-fold elevated for all four affected males. The enzyme was more sensitive to product inhibition by IMP and GMP than controls, and exhibited greater thermal lability at 65 degrees C than found with control lysates.
...
PMID:Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase with reduced affinity for PP-ribose-P in four related males with gout. 620 22
We have developed a method for the direct analysis of a
hypoxanthine-guanine phosphoribosyltransferase
(
HPRT
) allele associated with a deficiency of enzyme activity and an early onset of
gout
. The functionally abnormal enzyme coded for by this mutant allele (HPRTToronto) differs from the normal enzyme by an arginine-to-glycine substitution at position 50. A single base change in the codon for arginine 50 can explain this substitution. Direct analysis of this point mutation is based on the observation that it abolishes a Taq I recognition site in
HPRT
DNA. As predicted, DNA from individuals with the HPRTToronto allele exhibited an abnormal restriction pattern when digested with Taq I and probed with
HPRT
complimentary DNA: a normal 2.0-kb fragment is replaced by a 4.0-kb fragment. The 4.0/2.0-kb restriction fragment variation was used to detect the HPRTToronto allele in a heterozygote that was otherwise normal with respect to the classical techniques used to diagnose heterozygosity in
HPRT
deficiency.
...
PMID:Human hypoxanthine-guanine phosphoribosyltransferase. Detection of a mutant allele by restriction endonuclease analysis. 630 10
HPRTMunich is a mutant form of human
hypoxanthine-guanine phosphoribosyltransferase
that was isolated from a patient who presented with
gout
and a partial deficiency of enzyme activity. Profound abnormalities in the catalytic function of HPRTMunich are responsible for the deficiency of enzyme activity in vivo. Tryptic peptides of HPRTMunich were mapped by reverse phase high pressure liquid chromatography in an attempt to define the precise abnormality in its primary structure. Sequence analysis of aberrant peptides localized the structural alteration in HPRTMunich to residue 103. Several additional findings suggest that the mutation in this variant is most likely a serine to arginine substitution at residue 103. This amino acid substitution lies within the putative hypoxanthine-binding site of human
hypoxanthine-guanine phosphoribosyltransferase
possibly explaining its selective effect on intrinsic enzyme activity and binding of hypoxanthine.
...
PMID:Human hypoxanthine-guanine phosphoribosyltransferase. Structural alteration in a dysfunctional enzyme variant (HPRTMunich) isolated from a patient with gout. 670 36
A mutant form of human
hypoxanthine-guanine phosphoribosyltransferase
(HPRTToronto) was isolated from erythrocytes of a male patient with
gout
due to a partial deficiency of enzyme activity. The tryptic peptides of HPRTToronto were mapped by reverse-phase high pressure liquid chromatography in an attempt to define the precise abnormality in its primary structure. Sequence analysis of the single aberrant peptide in HPRTToronto revealed an arginine to glycine amino acid substitution at position 50. A single nucleotide change in the codon for arginine 50 (CGA leads to GGA) could explain this substitution.
...
PMID:Human hypoxanthine-guanine phosphoribosyltransferase. 685 90
The contribution of enhanced purine salvage to the decreased total purine excretion associated with allopurinol therapy was measured by the intravenous administration of tracer doses of [8-(14)C] adenine to four patients with
gout
and normal purine salvage enzyme activity and four patients with the
Lesch-Nyhan syndrome
and absent purine salvage activity. The mean cumulative excretion of radioactivity 5 days after the adenine administration to patients not receiving and receiving (off and on) allopurinol therapy was 6.1% and 3.6% of infused radioactivity for gouty subjects and 15.9% and 20.8% for the Lesch-Nyhan patients. Urate pool size and urate turnover, as measured by pool labeling with [2-(14)C]uric acid, were substantially decreased in both groups of patients during allopurinol therapy. The intestinal loss of uric acid was estimated from these pool measurements on and off allopurinol. With a correction for this extrarenal purine loss, the mean cumulative excretions of radioactivity 5 days after adenine administration to patients off and on allopurinol therapy were 11.9% and 4.8% for the gouty subjects and 31.7% and 24.5% for the Lesch-Nyhan patients. In vitro studies demonstrated no alteration of the synthesis or degradation of adenine nucleotides by allopurinol in cultured human diploid fibroblasts. These observations suggest that enhanced purine salvage is an important component leading to decreased purine excretion during allopurinol therapy.
...
PMID:Enhanced purine salvage during allopurinol therapy: an important pharmacologic property in humans. 729 39
Information on a familial syndrome of hyperuricemia and renal disease with or without
gout
was obtained on 33 of 41 blood relatives: Nine had renal disease; abnormalities of the urinary sediments were minimal; serum uric acid levels were elevated in seven and were not measured in two. Hyperuricemia was noted in three additional family members without evidence of renal disease. Goulty arthritis (three patients) did not precede renal disease. One individual had hyperuricosuria. The following erythrocyte purine enzyme levels were normal: adenine phosphoribosyltransferase,
hypoxanthine-guanine phosphoribosyltransferase
, phosphoribosylpyrophosphate, synthetase, adenosine deaminiase, and purine nucleoside phosphorylase. Renal biopsy specimens showed focal global and segmental sclerosis of glomeruli, occasional hypercellularity, foci of atrophic tubules, chronic interstitial inflammation, and folding and wrinkling of glomerular basement membrane without electron-dense deposits. There were no immunofluorescent abnormalities.
...
PMID:Familial hyperuricemia and renal disease. 739 93
<< Previous
1
2
3
4
5
6
7
8
Next >>